Holen Sie sich die Stockscreener-App
23.36
1.28%
0.295
Vorhandelsmarkt:
23.00
-0.36
-1.54%
Vor Biopharma Inc Aktie (VOR) Neueste Nachrichten
How Investors Are Reacting To Vor Biopharma (VOR) Sharply Narrowed Losses And Earnings Profile Shift - simplywall.st
Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold - MarketBeat
Vor Biopharma (VOR) sees Venrock-led group report 9.99% ownership stake - Stock Titan
Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership - Stock Titan
Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright - MarketBeat
VOR|Vor Biopharma Inc|Price:23.260|Chg%:+0.920 - TradingKey
Verve Capital Limited (VOR) reports 6.3% stake in Vor Biopharma common stock - Stock Titan
Citi Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright - MarketBeat
Vor Biopharma (VOR) Stock Looks Reasonable On Earnings Yet Weak On Broader Checks - Sahm
VOR BIOPHARMA INC. : WEDBUSH RAISES TARGET PRICE TO $27 FROM $18 - webull.com
VOR Maintains Rating by Wedbush -- Price Target Raised to $27.00 - GuruFocus
Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price - MarketBeat
Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings - MarketBeat
Wells Fargo Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Vor Biopharma (VOR) Reports Improved Cash Position and Reduced L - GuruFocus
Vor Biopharma Reports Q2 2026 Financial Results in SEC Form 10-Q Filing - Kalkine Media
Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate - scanx.trade
Vor Biopharma (NASDAQ:VOR) Posts Earnings Results - MarketBeat
Vor Biopharma (VOR) Strengthens Cash Position Amid Unprofitable Operations - GuruFocus
VOR Stock Update: Telitacicept Advances Amid Mixed Financial Sig - GuruFocus
Vor Biopharma Shares Drop After Q2 Results - marketscreener.com
Vor Biopharma Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Vor Biopharma posts wider-than-expected Q2 loss on increased G&A costs - TradingView
Earnings Flash (VOR) Vor Biopharma Posts Q2 Net Loss $1.16 a Share, vs. FactSet Est of $0.70 Loss - marketscreener.com
Vor Biopharma Inc. 2Q 2026: Net loss $(62.8M), EPS $(1.16) — 10-Q Summary - TradingView
Vor Biopharma (VOR) cuts losses as telitacicept trials advance and cash runway reaches 2029 - Stock Titan
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Renaissance Technologies LLC Makes New $2.30 Million Investment in Vor Biopharma Inc. $VOR - MarketBeat
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Analysts - marketbeat.com
VOR Q1 2026 Earnings: Deeper-than-Expected Loss Highlights Pre-Commercial Cash BurnPost-Announcement Reaction - Vinanet
Vor Biopharma Inc (VOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FMR LLC discloses 12% VOR Biopharma (VOR) stake for Abigail P. Johnson - Stock Titan
FMR LLC shows 9.1% Vor Biopharma (VOR) stake in Schedule 13G - Stock Titan
BlackRock, Inc. Expands Vor Biopharma (VOR) Stake with Strategic Add Transaction - GuruFocus
Vor Biopharma investors brace for earnings after massive Q1 loss By Investing.com - Investing.com
VOR Q2'26 Earnings: EPS estimate is (0.70) USD - TradingView
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
VOR Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Vor Biopharma Inc (VOR) Income Statement - TradingKey
Vor Biopharma (VOR) Slips Over 3% as Biotech Sector Struggles, Key Support in FocusPrice Gap Fill - vinanet.vn
Vor Biopharma Inc (VOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vor Biopharma Inc (VOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vor Biopharma Inc (VOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vor Biopharma Market Sentiment - Benzinga España
Vor Biopharma Inc (VOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vor Biopharma Inc (VOR) Institutional Confidence - TradingKey
Vor Biopharma Inc (VOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vor Biopharma Inc (VOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
VOR|Vor Biopharma Inc|Price:19.260|Chg%:+0.280 - TradingKey
TradingKey - TradingKey
Vor Biopharma Inc. Revenue Breakdown – NASDAQ:VOR - TradingView
Vor Biopharma (VOR) Edges Higher, Approaches Key Resistance at $20.22Bearish Pattern Stocks - Vinanet
Vor Biopharma (VOR) Stock May Already Look Fully Priced On Pipeline Hopes - Sahm
ETFs Investing in Vor Biopharma, Inc. Stocks - TradingView
Ra Capital Management’s fund sells $4,206 in Vor Biopharma stock By Investing.com - Investing.com South Africa
Ra Capital Management’s fund sells $4,206 in Vor Biopharma stock - Investing.com
Form 13D/A VOR BIOPHARMA INC. For: 22 July By Investing.com - Investing.com Nigeria
Form 4 Vor Biopharma Inc For: 22 July By Investing.com - Investing.com Nigeria
RA Capital exercises 2,100,000 Vor Biopharma (VOR) pre-funded warrants - Stock Titan
Vor Biopharma Inc. (VOR) holder exercises 2,100,000 pre-funded warrants - Stock Titan
Price to sales forward of Vor Biopharma Inc. – NASDAQ:VOR - TradingView
VOR Q1 2026 Earnings: Significant EPS Miss Amid Development-Stage OperationsEarnings Surprise Score - vinanet.vn
Vor Biopharma (NASDAQ:VOR) Shares Down 5%Here's Why - MarketBeat
1.21%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):